Galectin Therapeutic GALT

$3.52 -0.02 (-0.56%)

Valuation

Market cap
233,134,000
Revenue TTM
$0
Net income TTM
$-30,840,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
-0.76

Trading

Volume
263,800
Avg volume
265,880
Day's range
$3.45 – $3.70
Shares out
65,857,000
Stochastic %K
67%
Beta
0.38
Analysts
Sell
Price target
$11.00

Price

Company profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hyperte...

Show more

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Industry
Biotechnology
Sector
Healthcare
Phone
678 620 3186
Website
https://galectintherapeutics.com
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States

Latest news

Stocktwits

SNOWBALLDB321 Oct 30, 10:47 AM
$GALT Why no news is good news 30 days after a public company submits a phase 3 Protocol to the FDA. Phase 3 impact Clinical Hold impact: Because a Phase 3 trial is pivotal and often represents a core value driver, commercial prospect, or near-term revenue source for a biotech or pharmaceutical company, a clinical hold stopping or delaying a Phase 3 study is frequently material. SEC Form 8-K / Earnings / Press Releases: If the hold severely impacts the company's financial outlook, clinical timeline, or stock value, the company is typically obligated to issue a press release and/or file an SEC Form 8-K promptly (often within 4 business days of determining its material impact).
0 replies
Indibviduate1 Oct 30, 6:27 AM
$GALT
0 replies
Indibviduate1 Oct 30, 3:53 AM
$GALT 🧩🧩🧩🧩🥂🥂🥂🥂🥂🍾
1 replies
Indibviduate1 Oct 30, 3:46 AM
$GALT Did we just achieve a material event? Even if it’s not mandatory I can’t see any reason the company wouldn’t report this milestone to its investors. If we are now a phase 3 ready drug we have exactly what bp would want to trigger a buyout or major partnership. And they’ll have maximised value of the drug without major new investment or dilution. Great work Joel. Next week is going to be very very exciting. Just as aasld begins.
1 replies
Indibviduate1 Oct 30, 3:43 AM
$GALT Silent approval. And the vast majority of submissions safely clear the 30 days they are with the fda. Are we now a phase3 ready drug? That’s a huge increase in the company’s value if we are and exactly what is needed for a buyout/ partnership.
0 replies
Indibviduate1 Oct 30, 12:46 AM
$GALT it’s 30 days since the end of the third quarter and no material event announced so far. Are we a phase 3 ready drug now?
1 replies
swardfishtrader Oct 29, 8:55 PM
$GALT well at least we’re not IOVA today. Perfect world would be this moves over $10 so I can move profits into IOVA before it’s next move up early spring.
2 replies
JBRUN Oct 29, 3:44 PM
$GALT volume today looks a lot better than yesterday
0 replies